233 related articles for article (PubMed ID: 30648968)
1. Reprogramming the antigen specificity of B cells using genome-editing technologies.
Voss JE; Gonzalez-Martin A; Andrabi R; Fuller RP; Murrell B; McCoy LE; Porter K; Huang D; Li W; Sok D; Le K; Briney B; Chateau M; Rogers G; Hangartner L; Feeney AJ; Nemazee D; Cannon P; Burton DR
Elife; 2019 Jan; 8():. PubMed ID: 30648968
[TBL] [Abstract][Full Text] [Related]
2. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
Hwang JK; Wang C; Du Z; Meyers RM; Kepler TB; Neuberg D; Kwong PD; Mascola JR; Joyce MG; Bonsignori M; Haynes BF; Yeap LS; Alt FW
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):8614-8619. PubMed ID: 28747530
[TBL] [Abstract][Full Text] [Related]
3. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells.
Hartweger H; McGuire AT; Horning M; Taylor JJ; Dosenovic P; Yost D; Gazumyan A; Seaman MS; Stamatatos L; Jankovic M; Nussenzweig MC
J Exp Med; 2019 Jun; 216(6):1301-1310. PubMed ID: 30975893
[TBL] [Abstract][Full Text] [Related]
4. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.
Willis JR; Finn JA; Briney B; Sapparapu G; Singh V; King H; LaBranche CC; Montefiori DC; Meiler J; Crowe JE
Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4446-51. PubMed ID: 27044078
[TBL] [Abstract][Full Text] [Related]
5. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire.
Ou T; He W; Quinlan BD; Guo Y; Tran MH; Karunadharma P; Park H; Davis-Gardner ME; Yin Y; Zhang X; Wang H; Zhong G; Farzan M
Mol Ther; 2022 Jan; 30(1):184-197. PubMed ID: 34740791
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors.
Wang X; Ray R; Kratochvil S; Melzi E; Lin YC; Giguere S; Xu L; Warner J; Cheon D; Liguori A; Groschel B; Phelps N; Adachi Y; Tingle R; Wu L; Crotty S; Kirsch KH; Nair U; Schief WR; Batista FD
EMBO J; 2021 Jan; 40(2):e105926. PubMed ID: 33258500
[TBL] [Abstract][Full Text] [Related]
8. DSB structure impacts DNA recombination leading to class switching and chromosomal translocations in human B cells.
So CC; Martin A
PLoS Genet; 2019 Apr; 15(4):e1008101. PubMed ID: 30946744
[TBL] [Abstract][Full Text] [Related]
9. Insights into the B cell specific process of immunoglobulin class switch recombination.
Kracker S; Durandy A
Immunol Lett; 2011 Aug; 138(2):97-103. PubMed ID: 21324342
[TBL] [Abstract][Full Text] [Related]
10. Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells.
Pesch T; Bonati L; Kelton W; Parola C; Ehling RA; Csepregi L; Kitamura D; Reddy ST
Front Immunol; 2019; 10():2630. PubMed ID: 31798579
[TBL] [Abstract][Full Text] [Related]
11. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
12. Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching.
Dong J; Panchakshari RA; Zhang T; Zhang Y; Hu J; Volpi SA; Meyers RM; Ho YJ; Du Z; Robbiani DF; Meng F; Gostissa M; Nussenzweig MC; Manis JP; Alt FW
Nature; 2015 Sep; 525(7567):134-139. PubMed ID: 26308889
[TBL] [Abstract][Full Text] [Related]
13. Multiplex Gene Disruption by Targeted Base Editing of Yarrowia lipolytica Genome Using Cytidine Deaminase Combined with the CRISPR/Cas9 System.
Bae SJ; Park BG; Kim BG; Hahn JS
Biotechnol J; 2020 Jan; 15(1):e1900238. PubMed ID: 31657874
[TBL] [Abstract][Full Text] [Related]
14. Stochastic pairing of Ig heavy and light chains frequently generates B cell antigen receptors that are subject to editing in vivo.
Novobrantseva T; Xu S; Tan JE; Maruyama M; Schwers S; Pelanda R; Lam KP
Int Immunol; 2005 Apr; 17(4):343-50. PubMed ID: 15710909
[TBL] [Abstract][Full Text] [Related]
15. In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies.
Yin Y; Guo Y; Jiang Y; Quinlan B; Peng H; Crynen G; He W; Zhang L; Ou T; Bailey CC; Farzan M
Nat Biomed Eng; 2024 Apr; 8(4):361-379. PubMed ID: 38486104
[TBL] [Abstract][Full Text] [Related]
16. An in vivo method for diversifying the functions of therapeutic antibodies.
Tian M; Cheng HL; Kimble MT; McGovern K; Waddicor P; Chen Y; Cantor E; Qiu M; Tuchel ME; Dao M; Alt FW
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33658386
[TBL] [Abstract][Full Text] [Related]
17. Genome edited B cells: a new frontier in immune cell therapies.
Rogers GL; Cannon PM
Mol Ther; 2021 Nov; 29(11):3192-3204. PubMed ID: 34563675
[TBL] [Abstract][Full Text] [Related]
18. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.
Hashimoto S; Dono M; Wakai M; Allen SL; Lichtman SM; Schulman P; Vinciguerra VP; Ferrarini M; Silver J; Chiorazzi N
J Exp Med; 1995 Apr; 181(4):1507-17. PubMed ID: 7535340
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.
Wang Y; Wang S; Chen W; Song L; Zhang Y; Shen Z; Yu F; Li M; Ji Q
Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217854
[No Abstract] [Full Text] [Related]
20. Contribution of receptor editing to the antibody repertoire.
Casellas R; Shih TA; Kleinewietfeld M; Rakonjac J; Nemazee D; Rajewsky K; Nussenzweig MC
Science; 2001 Feb; 291(5508):1541-4. PubMed ID: 11222858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
